UltraSight Advances AI-Enabled Cardiac Imaging Workflows

FDA clears new tool to support echocardiography for patients with microaxial flow pumps

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

UltraSight, a leader in AI-guided cardiac imaging, announced FDA clearance of PVAD IQ, a new tool designed to help clinical teams improve access to consistent, rapid echocardiography imaging and pump position assessment for patients on microaxial flow pumps. These pumps are increasingly used to manage cardiogenic shock and high-risk cardiac interventions, but timely echocardiographic assessment remains resource-intensive. PVAD IQ incorporates insights from a feasibility study and is intended to enable a range of healthcare providers to acquire diagnostic-quality images under physician oversight.

Why it matters

Timely and reliable insight into pump function and positioning is essential for patients supported by microaxial flow pumps. AI-guided focused cardiac ultrasound offers an opportunity to strengthen bedside pump position assessment and help care teams make faster, more confident decisions to improve coordination across interventional cardiology, heart failure, and critical care.

The details

PVAD IQ is designed to help clinical teams improve access to consistent, rapid bedside imaging to support pump position assessment and patient management. UltraSight's AI-enabled Echosystem enables a range of healthcare providers including Advanced Practice Providers (APPs), intensivists, and clinicians who have not previously performed echocardiography to acquire diagnostic-quality images under qualified physician oversight.

  • UltraSight announced FDA clearance of PVAD IQ on February 25, 2026.

The players

UltraSight

A leader in AI-guided cardiac imaging workflows.

Ramya Singh

Chief Commercial Officer at UltraSight.

Mark Bieniarz, MD, FACC, FSCAI

Interventional Cardiologist at the New Mexico Heart Institute, Lovelace Medical Group, and member of the UltraSight Medical Advisory Board.

Got photos? Submit your photos here. ›

What they’re saying

“AI-enabled imaging is transforming how clinicians manage complex cardiac cases. With PVAD IQ, we're helping care teams implement scalable, consistent approaches to patient management—bringing clarity and confidence to some of the most demanding care environments.”

— Ramya Singh, Chief Commercial Officer

“For patients supported by microaxial flow pumps, timely and reliable insight into pump function and positioning is essential. AI-guided FoCUS offers a meaningful opportunity to strengthen bedside pump position assessment.”

— Mark Bieniarz, MD, FACC, FSCAI, Interventional Cardiologist

What’s next

Plans for formal market introduction of PVAD IQ remain under development to ensure alignment with evolving clinical workflows.

The takeaway

AI-guided focused cardiac ultrasound is transforming how clinicians manage complex cardiac cases, enabling a range of healthcare providers to acquire diagnostic-quality images and support essential patient management decisions, particularly for those on microaxial flow pumps.